The first under-the-nose nasal cradle mask with front-end tubing and our lightest mask yet*
Simply designed, with a slip-on headgear that puts patients at ease
Minimalist design also offers comfort and performance, making it a well-rounded option for a wide range of patients
Grab-n-go at setup
ResMed AirFit™ N30 is simply designed, which allows accurate size and fit right out of the package. Its under-the-nose nasal cradle cushion is color-coded for size and made from a soft silicone material that conforms to the shape of the nose. And its QuickFit™ elastic headgear slips on and off like a pair of swim goggles. The headgear also features a tiny, single-sided clip for making minor adjustments if needed.
Simplicity from the start
AirFit N30 is designed to make adjusting to therapy easier than ever before. Patients can feel confident wearing this mask around loved ones because it’s small, lightweight and features ResMed QuietAir™ technology – diffused venting that breaks up exhaled air to help minimize sleep disruptions. And with a simple design that fits discreetly into your life, AirFit N30 helps you on the right path to compliance. A recent study shows that, on average, CPAP users sleep much longer each day – 46 minutes more, in fact – with AirFit N30 compared to their current ResMed mask.1†
Patient adherence is key
While many masks excel in one or two areas, AirFit N30 is a well-rounded mask that has it all – a unique combination of comfort, performance and easy-to-use features packed into a simple and discreet design. And when paired with ResMed myAir™‡, you can keep track of your progress with a daily sleep score. With the right mask and engagement level, patients are empowered to take charge of their therapy, which can help improve adherence for a lifetime.
1 ResMed guided external clinical study of 17 evaluable CPAP mask users from Feb. 12–25, 2019 in Sydney, AU who trialed ResMed AirFit N30 at home for 7 nights in place of their prescribed mask, ResMed AirFit P10.
2 Combined responses of those expressing a preference in an independent patient survey in the UK, USA, France, Germany and Australia from March 2017.